<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609047</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC 1745-ETF-BCG</org_study_id>
    <nct_id>NCT03609047</nct_id>
  </id_info>
  <brief_title>Adjuvant Palbociclib in Elderly Patients With Breast Cancer</brief_title>
  <acronym>Appalaches</acronym>
  <official_title>A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Association of Breast Oncologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Adjuvant Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy&#xD;
      and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy&#xD;
      followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to assess the efficacy of the combination of at least&#xD;
      5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of&#xD;
      adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III&#xD;
      ER+/HER2- early breast cancer.&#xD;
&#xD;
      This is a two-arm open-label multi-center randomized (2:1) non-comparative phase II study in&#xD;
      elderly patients with stage II/III, ER+, HER2- early breast cancer for whom treatment with&#xD;
      chemotherapy is indicated.&#xD;
&#xD;
      Patients will be randomized with a 2:1 allocation rate to the following treatment arm:&#xD;
&#xD;
        -  experimental palbociclib arm: Standard adjuvant endocrine therapy for a duration of at&#xD;
           least 5 years + palbociclib for a total duration of up to 2 years.&#xD;
&#xD;
        -  control chemotherapy arm: adjuvant chemotherapy (4 cycles of&#xD;
           docetaxel/doxorubicin/epirubicin-cyclophosphamide; or of weekly paclitaxel D1, D8, and&#xD;
           D15 q3w if a 3 weekly schedule is not desired), followed by standard adjuvant endocrine&#xD;
           therapy for a duration of at least 5 years.&#xD;
&#xD;
      The primary endpoint of the study is the 3-year D-RFI rate in the experimental arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">June 13, 2032</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant recurrence-free interval (D-RFI) rate</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of permanent treatment discontinuation</measure>
    <time_frame>5 years after first patient inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Breast Cancer Stage II</condition>
  <condition>Breast Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>experimental palbociclib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control chemotherapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant chemotherapy:&#xD;
4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w&#xD;
Followed by standard adjuvant endocrine therapy for a duration of at least 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK4/6 inhibitor</description>
    <arm_group_label>experimental palbociclib arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel / cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin/cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin/cyclophosphamide</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Adjuvant Chemotherapy</description>
    <arm_group_label>control chemotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women or men with stage II or stage III, early invasive breast cancer according to the&#xD;
             UICC 8th edition for TNM classification&#xD;
&#xD;
          -  Histologically confirmed Estrogen Receptor ER+ (at least 10 % of cells staining&#xD;
             positive for ER), Human Epidermal Growth Factor Receptor 2 (HER-2) negative, early&#xD;
             invasive breast cancer based on results of local pathology. Testing may be performed&#xD;
             on diagnostic core biopsy or resection specimen.&#xD;
&#xD;
          -  In patients with multicentric, multifocal and/or bilateral breast cancer, all&#xD;
             histopathologically examined invasive tumors must meet pathologic criteria regarding&#xD;
             ER and HER2-status described above.&#xD;
&#xD;
          -  Adjuvant chemotherapy indicated and feasible according to treating physician and&#xD;
             patient, based on standard clinicopathological parameters (tumor size, lymph node&#xD;
             involvement, general health status, proliferation marker, patient wish) and gene&#xD;
             expression profile if available.&#xD;
&#xD;
          -  Adjuvant chemotherapy combining both anthracycline and taxanes considered not&#xD;
             indicated or not feasible according to treating physician.&#xD;
&#xD;
          -  No evidence of macroscopic distant metastases, investigated according to local&#xD;
             institutional guidelines.&#xD;
&#xD;
          -  Age ≥70 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2&#xD;
&#xD;
          -  Patient must have undergone breast +/- axillary surgery with curative intent for the&#xD;
             current malignancy ≤8 weeks before randomization.&#xD;
&#xD;
          -  The maximum duration from last surgery to the start of the first adjuvant treatment is&#xD;
             9 weeks.&#xD;
&#xD;
          -  Patients must have sufficient resolution of any surgical side effects from the last&#xD;
             surgery per physician assessment, with no active wound healing complications at the&#xD;
             time of randomization.&#xD;
&#xD;
          -  Incentive to undergo adjuvant radiation therapy when indicated per local institutional&#xD;
             guidelines.&#xD;
&#xD;
          -  Note: For patients in the palbociclib arm, radiation therapy when indicated has to&#xD;
             start ≤9 weeks after last surgery. The endocrine therapy can be initiated during or&#xD;
             after the radiation therapy but not later than 3 weeks after the last radiotherapy.&#xD;
             Palbociclib has to start ≤3 weeks after the last radiotherapy. When radiation therapy&#xD;
             is not indicated, endocrine therapy and palbociclib have to be initiated ≤9 weeks&#xD;
             after last surgery.&#xD;
&#xD;
          -  Note: For patients in the chemotherapy arm, chemotherapy has to be the first adjuvant&#xD;
             treatment and has to start ≤9 weeks after the last surgery. When radiation therapy is&#xD;
             indicated, this treatment has to start ≤6 weeks after the last chemotherapy&#xD;
             administration. Adjuvant endocrine therapy can be initiated during or after the&#xD;
             radiation therapy but not later than 3 weeks after the last radiotherapy. When&#xD;
             radiation therapy is not indicated, endocrine therapy has to be initiated ≤6 weeks&#xD;
             after last chemotherapy administration.&#xD;
&#xD;
          -  Adequate organ function, evidenced by the following laboratory results within 3 weeks&#xD;
             prior to inclusion:&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 upper limit of normal (ULN), or total bilirubin ≤ 3.0 × ULN in&#xD;
             patients with documented Gilbert's Syndrome.&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) ≥ 30 ml/min according to Modification of Diet in&#xD;
             Renal Disease (MDRD) formula or Chronic Kidney Disease - Epidemiology Collaboration&#xD;
             (CKD-EPI) formula or Cockcroft and Gault formula&#xD;
&#xD;
          -  Serum Glutamic Oxaloacetic Transaminase (Aspartate Transaminase), Serum Glutamic&#xD;
             Pyruvic Transaminase (Alanine Transaminase) and alkaline phosphatase ≤ 2.5 × ULN&#xD;
&#xD;
          -  Patients must be able and willing to swallow and retain oral medication without a&#xD;
             condition that would interfere with enteric absorption.&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be obtained&#xD;
             according to ICH/GCP, and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of invasive breast cancer&#xD;
&#xD;
          -  Systemic anticancer therapy prior to the breast cancer surgery&#xD;
&#xD;
          -  Prior therapy with any Cyclin-Dependent Kinase (CDK)4/6 inhibitor&#xD;
&#xD;
          -  Concurrent investigational agent within 28 days of randomization&#xD;
&#xD;
          -  Concomitant anticancer treatment with the exception of bone antiresorptive agents or&#xD;
             Luteinizing Hormone-Releasing Hormone agonists in male patients treated with an&#xD;
             aromatase-inhibitor&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of chemical or biological&#xD;
             composition similar to palbociclib or to chemotherapy components&#xD;
&#xD;
          -  Medications or substances that are potent inhibitors or inducers of CYP3A isoenzymes&#xD;
             within 7 days of randomization (see Chapter 5.6.3 for list of CYP3A inhibitors and&#xD;
             inducers)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection (including known HIV, active hepatitis B and/or hepatitis C infection),&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac&#xD;
             arrhythmia, or uncontrolled diabetes.&#xD;
&#xD;
          -  Other malignancy within the last 5 years except: adequately treated non-metastatic&#xD;
             non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal&#xD;
             carcinoma in situ of the breast.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Wildiers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+3227741611</phone>
    <email>1745@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Cornelis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet-Hopital Universitaire ULB</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissandra Dal Lago</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Vulsteke</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Wildiers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilig Hartziekenhuis Lier</name>
      <address>
        <city>Lier</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Troch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Jerusalem</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas - Campus SL</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Everaert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Martens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Chakiba-Brugere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-Lyon - Hopital Femme Mere Enfant</name>
      <address>
        <city>Brou</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse (CLCC)</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Levy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Priou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Mailliez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Venat-Bouvet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Terret</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hopital De La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital prive du Confluent - Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Lortholary</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon - Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Peron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Rigal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - l' Hopital de St Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Brain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mony Ung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattea Reinisch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Hoechst GmbH</name>
      <address>
        <city>Frankfurt Am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Rom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetskliniken Des Saarlandes</name>
      <address>
        <city>Homburg / Saar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erich-Franz Solomayer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ORTENAU KLINIKUM Offenburg-Gengenbach - Klinikum Offenburg Ebertplatz</name>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Frank</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Haematologie Gemeinschaftspraxis - Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Decker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Schwerte</name>
      <address>
        <city>Schwerte</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Balwanz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Hofmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Torgau</name>
      <address>
        <city>Torgau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eike Simon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Keller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hackmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Degli Infermi</name>
      <address>
        <city>Biella</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Seles</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Cretella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale B. Ramazzini</name>
      <address>
        <city>Carpi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katia Cagossi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riccione Hospital Unit - Ospedale Cervesi di Cattolica</name>
      <address>
        <city>Cattolica</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faenza Hospital Unit - Ospedale degli Infermi</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino &quot;IST&quot; - IRCCS - AUO San Martino - IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Ballestrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Guastalla</name>
      <address>
        <city>Guastalla</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Giovanardi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AULSS 9 - Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bonetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lugo Hospital Unit -Ospedale Umberto I</name>
      <address>
        <city>Lugo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Omarini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Elena Cazzaniga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rimini Hospital Unit - Ospedale Sacra Famiglia</name>
      <address>
        <city>Novafeltria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.P.A.</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Gebbia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna - Rimini Hospital Unit - Infermi Hospital</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino - Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Sant'Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Bau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hikmat Abdel-Razeq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Senkus-Konefka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska - Curie's National Institute of Oncology - National Research Institute</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Nowecki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Champalimaud Clinical Center</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berta Sousa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto-- Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemia Afonso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues De Oncologia - Instituto Portugues de Oncologia do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Pousa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universitari de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vidal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Arumi de Dios</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Martinez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau De Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serafin Morales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico MD Anderson</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Calvo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Echarri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lema</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario QuironSalud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Gonzalez Cortijo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitales HM Sanchinarro-CIOCC</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Vega</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Masvidal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Salvador Bofill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocio University Hospital</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Virizuela Echaburu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano De Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Gavila</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario De Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begona Bermejo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust - Blackpool Victoria Hospital-NHS Fundation Trust</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Bezecny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Lothian - Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Michie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust - St. Bartholomew'S Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schmid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Borders - Borders General Hospital Melrose By-pass</name>
      <address>
        <city>Melrose</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Bedi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>elderly patients</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

